Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-22

From a Stock head article Jan 31 2024

Neuroscientific Bio’s shares up after updateNeuroScientific Biopharma (ASX:NSB) surged 11.5% this morning after detailing its activities in the last quarter.In the December quarter,
NSB collated all data and requested a Type B, Pre-IND Meeting with the FDA with regards to EmtinB – the company’s lead drug designed to treat neurodegenerative conditions like Multiple Sclerosis and Alzheimer’s disease.

NSB is currently working with highly experienced consultants in the UK, EU, US and Australia, to gain as much insight from the FDA and confirm that the development plan for the drug is in place.

Meanwhile, results from the Early Phase Clinical Study data of EmtinB are expected in Q1 this year.

Separately, NSB says it continues to evaluate new and promising programs to provide the company with a pipeline of projects.
NeuroScientific’s cash position was $3.34 million as at 31 December.
The company says it has maintained a strong cash position with corporate expenses continuing to be carefully managed.
Finally, the level of net cash burn for the March 2024 quarter is expected to be at similar levels as for the December 2023 quarter.NSB says it wants to preserve cash in the coming months as the work towards the development of EmtinB commences.

IMO